Although pegylated IFN-α2a (Pegasys) is not licensed for the treatment, recent randomized trials revealed that it showed significantly greater complete hematologic as well as cytogenetic responses than those observed when unpegylated IFN-α was used in the treatment of CML patients. This evidence concerns the gene IFNA1 and chronic myelogenous leukemia, BCR-ABL1 positive.